Biomea Fusion Inc
BMEA1.585USD
+0.015+0.96%
Market hours （ET）Quotes delayed by 15 min
59.55MMarket Cap
LossP/E TTM
More Details of Biomea Fusion Inc Company
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Company Info
Ticker SymbolBMEA
Company nameBiomea Fusion Inc
IPO dateApr 16, 2021
CEODr. Michael J.M. (Mick) Hitchcock, Ph.D.
Number of employees106
Security typeOrdinary Share
Fiscal year-endApr 16
Address1599 Industrial Road
CitySAN CARLOS
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94070
Phone16509809099
Websitehttps://www.biomeafusion.com/
Ticker SymbolBMEA
IPO dateApr 16, 2021
CEODr. Michael J.M. (Mick) Hitchcock, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Rainer M. (Ramses) Erdtmann
Mr. Rainer M. (Ramses) Erdtmann
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
2.53M
--
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Lead Independent Director
Lead Independent Director
200.00
--
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Juan Pablo Fras
Dr. Juan Pablo Fras
Chief Medical Officer, Head of Diabetes
Chief Medical Officer, Head of Diabetes
--
--
Dr. Elizabeth Faust, Ph.D.
Dr. Elizabeth Faust, Ph.D.
Independent Director
Independent Director
--
--
Ms. Sumita Ray, J.D.
Ms. Sumita Ray, J.D.
Independent Director
Independent Director
--
--
,
,
Senior Director, Investor Relations and Corporate Development
Senior Director, Investor Relations and Corporate Development
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Rainer M. (Ramses) Erdtmann
Mr. Rainer M. (Ramses) Erdtmann
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
2.53M
--
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Lead Independent Director
Lead Independent Director
200.00
--
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Juan Pablo Fras
Dr. Juan Pablo Fras
Chief Medical Officer, Head of Diabetes
Chief Medical Officer, Head of Diabetes
--
--
Dr. Elizabeth Faust, Ph.D.
Dr. Elizabeth Faust, Ph.D.
Independent Director
Independent Director
--
--
Ms. Sumita Ray, J.D.
Ms. Sumita Ray, J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jun 27
Updated: Fri, Jun 27
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
9.53%
Heights Capital Management, Inc.
7.80%
Cormorant Asset Management, LP
6.26%
Butler (Thomas Andrew)
5.22%
Erdtmann (Rainer M)
4.44%
Other
66.74%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
9.53%
Heights Capital Management, Inc.
7.80%
Cormorant Asset Management, LP
6.26%
Butler (Thomas Andrew)
5.22%
Erdtmann (Rainer M)
4.44%
Other
66.74%
Shareholder Types
Shareholders
Proportion
Investment Advisor
25.05%
Hedge Fund
11.10%
Individual Investor
9.95%
Investment Advisor/Hedge Fund
7.02%
Research Firm
1.11%
Bank and Trust
0.31%
Family Office
0.10%
Pension Fund
0.03%
Other
45.33%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
269
31.12M
54.57%
-2.04M
2025Q1
286
30.27M
56.89%
-6.92M
2024Q4
291
32.11M
88.62%
-5.43M
2024Q3
283
32.46M
89.61%
-9.72M
2024Q2
276
32.63M
90.57%
-17.02M
2024Q1
262
40.47M
112.52%
-6.23M
2023Q4
249
37.13M
103.84%
-10.53M
2023Q3
227
38.85M
108.96%
-7.82M
2023Q2
225
38.32M
108.02%
-4.44M
2023Q1
192
32.77M
97.40%
+4.19M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
5.44M
9.53%
--
--
Mar 31, 2025
Heights Capital Management, Inc.
4.45M
7.8%
+4.45M
--
Jun 17, 2025
Cormorant Asset Management, LP
3.57M
6.26%
--
--
Mar 31, 2025
Butler (Thomas Andrew)
2.97M
5.22%
--
--
Mar 31, 2025
Erdtmann (Rainer M)
2.53M
4.44%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.96M
3.44%
-43.41K
-2.16%
Mar 31, 2025
The Vanguard Group, Inc.
1.38M
2.42%
-23.05K
-1.65%
Mar 31, 2025
Two Sigma Investments, LP
963.36K
1.69%
-56.07K
-5.50%
Mar 31, 2025
Aisling Capital Management LP
798.76K
1.4%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
625.95K
1.1%
+21.81K
+3.61%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Micro-Cap ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
iShares Morningstar Small-Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
